As of today (2024-04-17), Biogen's share price is $192.10.
Biogen's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $10.66. Hence, Biogen's Price-to-Operating-Cash-Flow Ratio for today is 18.02.
The historical rank and industry rank for Biogen's Price-to-Operating-Cash-Flow or its related term are showing as below:
BIIB'
s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.05 Med: 14.93 Max: 35.31
Current: 18.02
During the past 13 years, Biogen's highest Price-to-Operating-Cash-Flow Ratio was 35.31. The lowest was 6.05. And the median was 14.93.
Biogen's Cash Flow from Operations per share for the
three
months ended in Dec. 2023 was $0.09.
Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $10.66.
During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Biogen was 12.10% per year.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -26.00% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was -23.60% per year.
During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 1.30% per year.
During the past 13 years, Biogen's highest 3-Year average Operating Cash Flow per Share Growth Rate was 203.40% per year. The lowest was -36.90% per year. And the median was 20.70% per year.
Biogen Price-to-Operating-Cash-Flow Historical Data
The historical data trend for Biogen's Price-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
|
Biogen Annual Data
|
|
Trend |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Price-to-Operating-Cash-Flow |
|
|
|
|
|
|
7.86 |
9.34 |
9.86 |
29.20 |
24.35 |
|
Biogen Quarterly Data
|
|
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Price-to-Operating-Cash-Flow |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
29.20 |
24.10 |
28.94 |
27.43 |
24.35 |
Competitive Comparison
For the Drug Manufacturers - General subindustry, Biogen's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biogen Price-to-Operating-Cash-Flow Distribution
For the Drug Manufacturers industry and Healthcare sector, Biogen's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Biogen's Price-to-Operating-Cash-Flow falls into.
Biogen Price-to-Operating-Cash-Flow Calculation
Biogen's Price-to-Operating-Cash-Flow ratio for today is calculated as
| Price-to-Operating-Cash-Flow Ratio | = | Share Price | / | Cash Flow from Operations per share (TTM) |
| = | 192.10 | / | 10.66 |
| = | 18.02 |
Biogen's Share Price of today is $192.10.
Biogen's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $10.66.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).
It can also be calculated from the numbers for the whole company:
Biogen (Biogen) Business Description
Traded in Other Exchanges
Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.
Executives
| Priya Singhal |
officer: Head of Development |
C/O ZAFGEN, INC., 175 PORTLAND STREET 4TH FL, BOSTON MA 02114 |
| Jane Grogan |
officer: Head of Research |
BIOGEN INC., 225 BINNEY STREET, CAMBRIDGE MA 02142 |
| Susan Langer |
director |
BIOGEN INC., 225 BINNEY STREET, CAMBRIDGE MA 02142 |
| Ginger Gregory |
officer: EVP, Human Resources |
C/O BIOGEN INC., 225 BINNEY ST., CAMBRIDGE MA 02142 |
| Adam Keeney |
officer: Head of Corporate Development |
BIOGEN INC., 225 BINNEY STREET, CAMBRIDGE MA 02142 |
| Christopher Viehbacher |
director, officer: President and CEO |
C/O AXCELLA HEALTH, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
| Susan H Alexander |
officer: EVP, General Counsel |
C/O BIOGEN IDEC INC., 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142 |
| Nicole Murphy |
officer: Head of Pharm Ops and Tech |
BIOGEN INC., 225 BINNEY STREET, CAMBRIDGE MA 02142 |
| Rachid Izzar |
officer: Head of Alzheimer's Disease |
BIOGEN INC., 225 BINNEY STREET, CAMBRIDGE MA 02142 |
| Chirfi Guindo |
officer: EVP Glob. Mkt Acc & Cust Innov |
C/O BIOGEN INC., 225 BINNEY ST., CAMBRIDGE MA 02142 |
| Alfred Sandrock |
officer: Grp SVP, Chief Medical Officer |
14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142 |
| Brian S Posner |
director |
14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142 |
| Jones William D /ca/ |
director |
|
| Maria C Freire |
director |
C/O ALEXANDRIA REAL ESTATE EQUITIES, INC, 26 NORTH EUCLID AVENUE, PASADENA CA 91101 |
| Jesus B Mantas |
director |
BIOGEN INC., 225 BINNEY STREET, CAMBRIDGE MA 02142 |
Biogen (Biogen) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BIIB has been successfully added to your